EUVIMEDEUVIMED entdecken
Crossref

Mitochondrial-Targeting Zwitterionic Nanomedicine Based on Tertiary Amine N ‑oxide Polymers for Triple-Negative Breast Cancer Therapy

Yuxin Huang, Wenya Zhu, Jiaxin Zhang, Yichen Zhang, Yuxin Liu, Guowei Wang iD, Wuli Yang iD

Biomacromolecules · 13.10.2025 · 26 (10) · 7125-7139

DOI: 10.1021/acs.biomac.5c01461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 08.09.2025. Verfasst von Yuxin Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Mitochondria, Nanomedicine, Polymers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Program of Shanghai Academic Research Leader.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) remains a formidable clinical challenge due to its aggressive behavior, lack of therapeutic targets, and poor prognosis. The PI3K/AKT/mTOR pathway is highly activated in TNBC, making it a promising therapeutic target. Conventional PEGylated nanocarriers often face challenges, such as accelerated blood clearance and lysosomal trapping. To overcome these limitations, we developed a zwitterionic block copolymer, poly­(2-(N-oxide-dimethylamino)­ethyl methacrylate)-block-poly­(ε-caprolactone) (OPDMA-PCL), via one-pot living anionic polymerization followed by postmodification. Compared with poly­(ethylene glycol)-block-poly­(ε-caprolactone) (PEG-PCL) micelles, the OPDMA-PCL micelles exhibited prolonged systemic circulation, improved tumor targeting, and negligible immunogenicity. OPDMA-PCL micelles exhibited mitochondria-targeting properties in vitro. Loaded with gambogenic acid (GNA), OPDMA-PCL-GNA induces apoptosis in MDA-MB-231 cells by inhibiting the PI3K/AKT/mTOR pathway. In vivo, OPDMA-PCL-GNA achieved 91.2% tumor growth inhibition in xenograft models without systemic toxicity. This work establishes zwitterionic OPDMA-PCL micelles as a promising platform for TNBC therapy, overcoming key limitations of PEGylated systems while enabling organelle-specific drug delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsMitochondriaNanomedicinePolymersHumansFemaleAnimalsMicellesMiceCell Line, TumorApoptosisPolyethylene GlycolsPolyestersMice, Inbred BALB CMice, NudeDrug CarriersMethacrylatesXenograft Model Antitumor Assays

Substanzen

MicellesPolymersPolyethylene GlycolsPolyestersDrug CarriersMethacrylates

Autor:innen und Institutionen

  • State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200433, China.

ORCID-Profile: Guowei Wang, Wuli Yang

Förderung

  • National Natural Science Foundation of China
  • Program of Shanghai Academic Research Leader

Zitieren

APA

Huang, Y., Zhu, W., Zhang, J., Zhang, Y., Liu, Y., Wang, G., & Yang, W. (2025). Mitochondrial-Targeting Zwitterionic Nanomedicine Based on Tertiary Amine N ‑oxide Polymers for Triple-Negative Breast Cancer Therapy. Biomacromolecules, 26(10), 7125-7139. https://doi.org/10.1021/acs.biomac.5c01461

Vancouver

Huang Y, Zhu W, Zhang J, Zhang Y, Liu Y, Wang G, et al. Mitochondrial-Targeting Zwitterionic Nanomedicine Based on Tertiary Amine N ‑oxide Polymers for Triple-Negative Breast Cancer Therapy. Biomacromolecules. 2025;26(10):7125-7139. doi:10.1021/acs.biomac.5c01461

BibTeX
@article{Huang2025,
  author = {Huang, Yuxin and Zhu, Wenya and Zhang, Jiaxin and Zhang, Yichen and Liu, Yuxin and Wang, Guowei and Yang, Wuli},
  title = {Mitochondrial-Targeting Zwitterionic Nanomedicine Based on Tertiary Amine N ‑oxide Polymers for Triple-Negative Breast Cancer Therapy},
  journal = {Biomacromolecules},
  year = {2025},
  volume = {26},
  number = {10},
  pages = {7125--7139},
  doi = {10.1021/acs.biomac.5c01461}
}
Kostenlos starten →